Copenhagen, Denmark, May 2026 – Orifarm has announced the appointment of Pierre Bourdage as a new member of its Board of Directors, effective May 1, 2026, strengthening the company’s leadership as it accelerates its long-term European growth ambitions.
Pierre Bourdage brings more than two decades of international leadership experience across the pharmaceutical and healthcare industries, with deep expertise in commercial strategy, portfolio management, licensing, mergers & acquisitions, biosimilars, generics, innovative pharmaceuticals, and MedTech.
Most recently, Pierre served as Chief Commercial Officer (CCO) at Sandoz, where he led the company’s global commercial strategy and operations, including portfolio and pipeline strategy, licensing and M&A activities, launches, global marketing operations, portfolio analytics, and the company’s B2B business unit. During his seven-year tenure at Sandoz, he played a significant role in scaling the company’s generics and biosimilars platform while supporting its long-term growth strategy.
Commenting on the appointment, Hans Bøgh-Sørensen, Owner and Chairman of the Board at Orifarm, said that Pierre brings a rare combination of strategic portfolio expertise and commercial leadership from some of the world’s largest pharmaceutical organizations, adding that his experience would be a strong asset as Orifarm continues expanding its European footprint.
Sharing his thoughts on joining the board, Pierre stated that he is pleased to become part of Orifarm’s Board of Directors at an important phase of the company’s development and looks forward to contributing his experience in global commercial strategy and portfolio leadership to support Orifarm’s continued growth across Europe.
Career Journey
Before joining the Board of Orifarm, Pierre Bourdage served as a healthcare advisor and investor, advising private equity firms on healthcare acquisitions while also supporting healthcare startups and innovation initiatives. He currently serves on multiple boards and remains actively involved in healthcare-focused investment and advisory activities.
At Sandoz, Pierre held several senior global leadership positions over more than seven years, including Chief Commercial Officer / Executive Vice President, Global Head of Biopharmaceuticals Business Unit, and Senior Vice President – Biopharma Strategy, Portfolio, BD&L and Alliances. During this period, he led global strategies across biosimilars and generics, portfolio expansion, business development, licensing, mergers and acquisitions, launches, and integrated commercial operations.
Prior to Sandoz, he served as Country President / Managing Director – UK & Ireland at Alcon, where he led the organization’s Surgical and Vision Care MedTech business across the region while overseeing strategic commercial functions and operational leadership.
Earlier in his career, Pierre spent nearly 15 years with Novartis in multiple leadership roles including Vice President – Neuroscience & Multiple Sclerosis Specialty Franchise, Vice President – Primary Care Franchise, and Group Marketing Director – Primary Care. His responsibilities included leading integrated commercial teams across marketing, sales, medical affairs, market access, and analytics functions for large specialty and primary care portfolios.
He also held earlier commercial and analytical roles across healthcare and investment organizations including ConvaTec Bristol Myers Squibb and PowerCorp, while additionally serving with the Canadian Armed Forces during the early stages of his professional journey.
About Orifarm
Orifarm is one of Europe’s leading suppliers of parallel imported and generic pharmaceuticals, focused on improving healthcare accessibility and affordability across international markets. The company provides high-quality pharmaceutical products while helping create value and cost savings for healthcare systems, societies, and consumers.
With a strong international presence, Orifarm continues to expand across Europe through innovation, strategic partnerships, and exploration of new business opportunities aimed at strengthening its position within the pharmaceutical sector.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
